Financial Performance - The company's revenue for the first half of 2022 was ¥458,623,415.18, representing a decrease of 15.65% compared to ¥543,741,814.47 in the same period last year[18]. - The net profit attributable to shareholders was a loss of ¥35,458,118.93, a decline of 185.72% from a profit of ¥41,363,224.78 in the previous year[18]. - The net cash flow from operating activities was negative at ¥59,211,866.34, down 168.94% from ¥85,892,967.97 in the same period last year[18]. - The total assets decreased by 8.57% to ¥878,561,062.71 from ¥960,876,447.77 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 10.87% to ¥584,127,603.18 from ¥655,330,600.73 at the end of the previous year[18]. - Basic earnings per share were reported at -¥0.58, a decrease of 165.17% compared to ¥0.89 in the same period last year[19]. - The company's operating revenue for the first half of 2022 was ¥458,623,415.18, a decrease of 15.65% compared to ¥543,741,814.47 in the same period last year[99]. - The net profit attributable to shareholders of the parent company was -35.46 million RMB, a decrease of 185.72% year-on-year[20]. - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was -38.37 million RMB, a decrease of 201.72% year-on-year[20]. Research and Development - The R&D expenditure as a percentage of revenue increased to 6.61%, up by 2.59 percentage points from 4.02% in the previous year[19]. - The company increased its R&D investment by 38.77% year-on-year, with total R&D expenses amounting to ¥30,310,519.16, representing 6.61% of operating revenue[43]. - The company applied for 171 new patents during the reporting period, including 7 invention patents and 40 design patents, bringing the total number of patents to 1,602[41]. - The number of R&D personnel increased to 123, accounting for 12.18% of the total workforce, up from 10.54% in the previous year[55]. - The average salary of R&D personnel rose to 15.78 million RMB, compared to 13.63 million RMB in the previous year, indicating a focus on attracting and retaining talent[55]. Market and Product Development - The company focuses on the innovation of health products, primarily engaged in the design, research and development, production, sales, and service of smart portable massagers[26]. - The global massage equipment market is expected to reach approximately 18.4 billion USD by 2022, with China's market growing from 10.6 billion RMB in 2016 to 15 billion RMB in 2022[27][28]. - The current market penetration rate of massage equipment in China is about 1.5%, indicating significant growth potential compared to 15%-20% in mature markets like Japan and South Korea[29]. - The company launched several new products, including the See 5R intelligent eye massager and the Neck 5 neck massager, to meet the growing consumer demand for high-quality health products[54]. - The company is focusing on product innovation to capture new market demands, particularly in the health and wellness sector, which is experiencing a shift towards quality-oriented consumption[54]. Operational Strategy - The company has implemented a new retail model that integrates online and offline sales channels, promoting collaborative development[32]. - The company is leveraging a new marketing model that combines hardware sales with consumable repurchases to enhance customer loyalty and service diversity[56]. - The intelligent product service system v3.0 was developed, which includes automated deployment and logging systems to improve operational efficiency[50]. - The company is implementing a cross-platform development strategy to enhance user experience and service delivery through mobile applications[50]. - The company is focusing on enhancing user interaction and satisfaction through advanced sensor technology and AI-driven health management solutions[48]. Financial Health and Investments - The company reported a significant increase in cash and cash equivalents, reaching ¥318,328,565.60, up 44.43% from ¥220,405,530.79 at the end of the previous year[101]. - The company's short-term borrowings increased by 900% to ¥100,000,000.00 from ¥10,000,000.00, indicating a shift in financing strategy[103]. - The company has invested a total of 926.19 million in the axial massage device upgrade project, with 208.37 million allocated in the current period and a cumulative investment of 617.52 million[47]. - The dual-axis sports massager project has a total investment of 569.37 million, with 232.41 million spent in the current period and a cumulative investment of 348.07 million[47]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential deals[132]. Challenges and Risks - The company is facing various operational risks, which are detailed in the report[4]. - The company faced challenges due to the COVID-19 pandemic, with significant declines in offline consumer traffic, particularly in transportation hubs, impacting sales[64]. - The company is at risk of losing market share if it fails to maintain technological leadership and timely product launches in a competitive environment[94]. - The company is facing risks from macroeconomic fluctuations and potential impacts from ongoing COVID-19 pandemic measures[90]. Shareholder and Governance - The company held its 2021 annual general meeting on May 16, 2022, where it approved the election of Fan Xiulian as a non-independent director[112]. - The company did not propose any profit distribution or capital reserve fund increase for the half-year period[115]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing, with a strict adherence to this commitment[123]. - Shareholders are restricted to transferring no more than 25% of their total shares held annually during their tenure and for six months after leaving the company[125]. - The company has committed to compensating for any economic losses caused by violations of related commitments[153].

Financial Performance - The company's operating revenue for Q1 2022 was ¥247,744,027.72, representing a year-on-year increase of 15.29%[5] - The net profit attributable to shareholders was a loss of ¥9,889,836.00, a decrease of 188.84% compared to the same period last year[5] - The basic earnings per share for the period was -¥0.16, reflecting a decline of 166.67%[6] - Total operating revenue for Q1 2022 was CNY 247,744,027.72, an increase of 15.3% compared to CNY 214,891,263.85 in Q1 2021[22] - Net profit for Q1 2022 was a loss of CNY 9,955,472.14, compared to a profit of CNY 11,020,385.39 in Q1 2021[23] - The total comprehensive income for Q1 2022 was -9,627,471.41 RMB, compared to 11,020,385.39 RMB in Q1 2021, indicating a significant decline[24] - Basic and diluted earnings per share for Q1 2022 were both -0.16 RMB, down from 0.24 RMB in Q1 2021[24] - Operating profit for Q1 2022 was RMB 444,550.92, a significant decrease from RMB 6,451,612.30 in Q1 2021[31] - Net profit for Q1 2022 was RMB 13,455.58, compared to RMB 6,605,170.14 in Q1 2021, indicating a decline in profitability[31] - The total comprehensive income for Q1 2022 was RMB 13,455.58, down from RMB 6,605,170.14 in Q1 2021, reflecting overall financial challenges[31] Expenses and Costs - Research and development expenses totaled ¥15,366,824.52, accounting for 6.20% of operating revenue, an increase of 1.27 percentage points year-on-year[6] - Management expenses increased by 51.73%, primarily due to rising salaries and increased consulting fees[10] - The company reported a significant increase in sales expenses, which rose to CNY 113,179,752.57 from CNY 90,400,638.22 in Q1 2021, a 25.2% increase[22] - Sales expenses rose to RMB 58,522,961.20 in Q1 2022, compared to RMB 42,594,629.08 in Q1 2021, indicating increased marketing efforts[30] Assets and Liabilities - The total assets at the end of the period were ¥904,417,146.92, down 5.88% from the end of the previous year[6] - The total assets decreased from CNY 960,876,447.77 in the previous year to CNY 904,417,146.92 in Q1 2022[19] - Total liabilities decreased from CNY 305,874,969.14 in the previous year to CNY 259,043,139.70 in Q1 2022[19] - The company's equity attributable to shareholders decreased from CNY 655,330,600.73 to CNY 645,768,765.46 year-over-year[19] - The company's total equity as of March 31, 2022, was 650,836,664.13 RMB, slightly up from 650,823,208.55 RMB at the end of 2021[29] Cash Flow - Cash flow from operating activities showed a net outflow of ¥71,633,390.31, with no applicable year-on-year comparison[5] - Cash inflows from operating activities totaled 291,523,989.09 RMB in Q1 2022, slightly up from 284,398,661.71 RMB in Q1 2021[25] - The net cash flow from operating activities was -71,633,390.31 RMB in Q1 2022, worsening from -16,841,814.86 RMB in Q1 2021[26] - The company reported a net cash flow from investing activities of 99,983,139.91 RMB in Q1 2022, a significant increase from 1,333,466.13 RMB in Q1 2021[26] - The company reported a significant increase in cash inflow from investment activities, totaling RMB 135,190,729.42 in Q1 2022, compared to RMB 6,000,000.00 in Q1 2021[33] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,171[12] - The largest shareholder, Ma Xuejun, holds 40.31% of the shares, totaling 24,848,471 shares[12] Revenue Breakdown - The company achieved online revenue of 163.97 million RMB, representing a year-over-year growth of 48.77%[15] - Offline revenue was 80.06 million RMB, showing a year-over-year decline of 15.38%[15] - Revenue for Q1 2022 reached RMB 194,582,743.14, a 33% increase from RMB 146,304,825.18 in Q1 2021[30] Strategic Initiatives - The company plans to hold a new product launch event in the second quarter of 2022, focusing on accelerating new product development and iteration[16] - The company is implementing a management transformation focused on "specialization and efficiency, digital transformation" to enhance long-term competitiveness[16] - The company is committed to product innovation and operational efficiency while controlling costs to mitigate the adverse effects of the pandemic[16] - The company is enhancing its online B2C channels and new media outreach to drive sales growth[15] - The company is focusing on user care in its marketing strategy to improve brand experience while maintaining exposure[15]

Financial Performance - The company's operating revenue for 2021 was CNY 1,189,539,638.54, representing a year-on-year increase of 43.93%[21]. - The net profit attributable to shareholders for 2021 was CNY 91,861,861.17, up 29.92% compared to the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 76,689,994.03, reflecting a growth of 22.23% year-on-year[21]. - Basic earnings per share for 2021 increased by 13.73% to CNY 1.74[22]. - The total assets at the end of 2021 reached CNY 960,876,447.77, a 101.78% increase from the previous year[21]. - The company's net assets attributable to shareholders rose to CNY 655,330,600.73, marking a significant increase of 179.49% year-on-year[21]. - The cash flow from operating activities for 2021 was CNY 86,917,959.84, an increase of 27.36% compared to 2020[21]. - The total cash dividend for the year, including the interim distribution, amounts to 66,941,040.00 RMB (including tax)[5]. - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares, totaling 36,984,000.00 RMB (including tax) for the year 2021[5]. Research and Development - Research and development expenses accounted for 3.97% of operating revenue in 2021, down from 4.46% in 2020[22]. - The company has increased R&D investment to enhance product competitiveness in areas such as usability, design, and user experience[30]. - The company achieved a total R&D investment of ¥47,204,969.72, representing a 27.96% increase compared to the previous year[69]. - The total R&D investment accounted for 3.97% of the operating revenue, a decrease of 0.49 percentage points from the previous year[69]. - The company added a total of 96 new patents during the reporting period, including 7 domestic invention patents and 8 overseas invention patents[58]. - The company holds a total of 672 domestic and international patents as of December 31, 2021, establishing itself as a leading brand in the smart portable massager industry[48]. - The company is committed to continuous innovation in health sensing technology, achieving breakthroughs in user-specific adaptations and individual feature recognition[64]. Market Expansion and Strategy - The company is exploring new franchise models to penetrate lower-tier markets, aiming to expand its consumer base by leveraging appropriate pricing strategies[43]. - The company has increased its marketing efforts on new media platforms like Douyin, WeChat, and Xiaohongshu, enhancing product exposure and consumer interaction through live streaming and promotional activities[44]. - The collaboration with Tonino Lamborghini has led to the launch of high-end massage products, enhancing brand recognition and supporting the company's international expansion strategy[45]. - The company is expanding its overseas market presence with subsidiaries in Hong Kong, the USA, and Japan, while also facing risks from international investment policies and management complexities[90]. - The company plans to expand its sales channels and increase efforts in overseas markets, particularly in the US, Russia, Japan, and Southeast Asia[141]. - The company aims to enhance its market competitiveness through breakthroughs in product innovation, focusing on intelligent, portable, and user-friendly designs[81]. Product Development and Innovation - The company launched the smart moxibustion box in Q3 2021, which received positive market feedback and expanded the moxibustion product line[32]. - The company launched the sixth generation portable head massager, featuring the industry's first dual-channel high-fidelity stereo audio online voice recognition module[64]. - The company upgraded its user-end APP platform, enhancing user engagement through new interactive technologies and features[65]. - The company is developing new technologies to enhance user data collection and health analysis capabilities, expanding its market potential[72]. - The integration of AI and IoT technologies in new products is expected to simplify user operations and improve health management services[72]. - The company aims to strengthen its competitive position in the eye care product line through innovative product upgrades and enhanced user interaction[73]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has established a cash dividend policy that protects the rights of minority investors, with no adjustments made during the reporting period[180]. - The company actively engages in corporate social responsibility, contributing to social welfare and environmental protection while enhancing its governance structure[187]. - The company has implemented a comprehensive internal control system, focusing on key areas such as sales, procurement, production, R&D management, and financial reporting, with no significant deficiencies identified[184]. Risks and Challenges - The company has detailed various risks and countermeasures in its report, particularly in the "Management Discussion and Analysis" section[4]. - The company faced risks related to high sales expense ratios due to a significant proportion of direct sales, leading to increased promotional and personnel costs[92]. - The company is at risk of declining gross margins if industry competition leads to lower product prices or if raw material costs rise without effective cost control[91]. - The company is actively addressing the impact of the COVID-19 pandemic on its direct sales performance, particularly in physical retail locations[95]. Employee and Management Information - The company employed a total of 1,083 staff members, with 348 in the parent company and 735 in major subsidiaries[176]. - The workforce includes 721 sales personnel, 126 technical staff, and 111 production workers, reflecting a strong focus on sales and technical capabilities[176]. - The education level of employees shows that 29 hold master's degrees or higher, while 314 have bachelor's degrees[176]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 9.5432 million yuan[163]. - Total remuneration for core technical personnel at the end of the reporting period was 838,500 yuan[163]. - Key personnel changes include the resignation of several executives, impacting the leadership structure[154].

证券代码：688793 证券简称：倍轻松 公告编号：2021-016 深圳市倍轻松科技股份有限公司 关于参加 2021 深圳辖区"沟通传递价值，交流创造良好生 态"上市公司投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要提示： 会议召开时间：2021年11月30日（星期二） 14:00-17:00 会议召开地点：全景•路演天下网络平台（网址：http://rs.p5w.net/）或关 注微信公众号：全景财经 会议召开方式：网络文字互动 深圳市倍轻松科技股份有限公司（以下简称"公司"）拟参加由深圳上市公 司协会、深圳市全景网络有限公司共同举办的"沟通传递价值，交流创造良好生 态" ——2021深圳辖区上市公司投资者网上集体接待日活动，现将有关事项公 告如下： 一、说明会类型 本次投资者集体接待日活动以网络文字互动形式召开，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2021年11月30日（星期二） 14:00-17:00 （二 ...

Financial Performance - The company's revenue for Q3 2021 was CNY 269,522,946.86, representing a year-over-year increase of 39.80%[5] - The net profit attributable to shareholders for Q3 2021 was CNY 24,615,645.06, an increase of 17.72% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date was CNY 59,822,476.95, reflecting a significant increase of 126.59%[6] - Basic earnings per share for Q3 2021 were CNY 0.44, with a year-to-date increase of 87.32%[6] - The net profit for Q3 2021 was CNY 65,924,537.85, a significant increase of 103.5% compared to CNY 32,425,480.38 in Q3 2020[26] - Operating profit for Q3 2021 reached CNY 78,099,346.91, up 102.5% from CNY 38,626,442.59 in the same period last year[26] - Total revenue from operating activities for the first nine months of 2021 was CNY 892,488,417.94, compared to CNY 557,992,703.57 in the first nine months of 2020, indicating a growth of 60%[28] - The company reported a total comprehensive income of CNY 66,193,480.60 for Q3 2021, compared to CNY 32,597,969.40 in Q3 2020, reflecting a growth of 102.5%[27] - Basic and diluted earnings per share for Q3 2021 were both CNY 1.33, compared to CNY 0.71 in Q3 2020, representing an increase of 87.3%[27] Assets and Liabilities - The total assets as of the end of the reporting period reached CNY 944,944,716.55, marking a 98.43% increase from the end of the previous year[6] - The company's total current assets amounted to CNY 783,187,420.71, up from CNY 435,360,309.81 in the previous year[23] - The company's cash and cash equivalents as of September 30, 2021, were CNY 445,993,162.65, compared to CNY 139,290,230.04 at the end of 2020, indicating a substantial increase in liquidity[21] - The company's inventory as of September 30, 2021, was CNY 203,137,314.50, up from CNY 140,591,605.10 in the previous year[21] - The total equity attributable to shareholders increased to CNY 629,767,867.53 from CNY 234,476,930.83, indicating strong growth in shareholder value[24] - Current liabilities totaled 240,781,058.82, with accounts payable at 153,041,599.72[33] - The company reported a total liability of 344,322,615.36, with non-current liabilities at 103,541,556.54[33] Cash Flow - The cash flow from operating activities for the year-to-date was CNY 58,647,955.17, with significant changes due to the implementation of new leasing standards[6] - The net cash flow from operating activities for Q3 2021 was CNY 58,647,955.17, a substantial increase from CNY 3,306,973.50 in Q3 2020[29] - The net cash flow from financing activities for Q3 2021 was CNY 255,627,722.48, compared to a negative CNY 11,214,455.97 in Q3 2020, indicating a turnaround in financing activities[30] - The company received CNY 390,677,620.00 from financing activities in Q3 2021, a notable increase from CNY 23,500,000.00 in the same period last year[30] Research and Development - The company's R&D investment totaled CNY 8,711,446.90 in Q3 2021, accounting for 3.23% of revenue, a decrease of 1.81 percentage points year-over-year[6] - The company established an industrial technology research institute to enhance R&D innovation capabilities and explore cutting-edge technology[16] - The company is actively enhancing its core R&D talent pool by introducing professional technical personnel and expanding external R&D collaborations[16] Market and Product Development - The company attributed the revenue growth to new product launches, increased promotional efforts, and expansion into new channels and customers[11] - New product launches in the second half of 2021 include the "Jiang Xiaozhu" smart moxibustion series, which received positive market feedback[17] - The company plans to hold a global product launch event in early November to introduce more traditional Chinese medicine technology products[17] - Online sales channels, including Douyin and cross-border e-commerce, have shown rapid growth, contributing to overall revenue stability[18] - The company optimized its after-sales service system and upgraded its digital marketing system to enhance user profiling for targeted marketing strategies[18] - The company aims to expand its offline presence primarily in shopping centers while adjusting operations in transportation hubs affected by COVID-19[17] Shareholder Information - The company reported a total of 3,362 common shareholders at the end of the reporting period[13] - The top shareholder, Ma Xuejun, holds 24,848,471 shares, representing 40.0% of the total shares[13] - The company reported a 2.5% shareholding by Anxin Securities Asset Management in the strategic allocation plan[14] Production Capacity - The company established a modern factory in Shenzhen to enhance its production capacity and product quality control[19]

Financial Performance - The company's revenue for the first half of 2021 was CNY 543.74 million, representing a year-on-year increase of 64.94%[21]. - Net profit attributable to shareholders was CNY 41.36 million, up 248.78% compared to the same period last year[21]. - The net profit after deducting non-recurring gains and losses was CNY 37.72 million, an increase of 377.68% year-on-year[21]. - The basic earnings per share increased by 242.31% to CNY 0.89[22]. - The company's gross profit margin for the reporting period was 60.89%, indicating a strong profitability position[119]. - The company reported a revenue of 7,663 million with a net profit of 2,427 million, maintaining a strong performance in the first half of 2021[101]. - The company reported a revenue of 5,209 million RMB for the first half of 2021, with a net profit of 1,480 million RMB, indicating a strong performance[103]. - The company reported a significant increase in revenue, achieving a total of 202 million in the first half of 2021, representing a year-on-year growth of 18%[162]. - Revenue for the first half of 2021 reached 200 million, representing a 25% increase compared to the same period last year[164]. - The company reported a significant increase in user data, with a year-on-year growth of 30% in active users[163]. Research and Development - The company reported a 35.61% increase in R&D expenses, totaling ¥21,842,182.20 compared to ¥16,106,196.35 in the previous period[97]. - R&D expenses accounted for 4.02% of total revenue, a decrease of 0.87% from the previous period[97]. - The company is focusing on enhancing its R&D capabilities by recruiting high-end talent and collaborating with medical research institutions[115]. - The company has increased its R&D personnel and project trial costs, contributing to the rise in R&D expenses[98]. - The company is investing $50 million in research and development for new technologies aimed at enhancing user experience[151]. - The company has committed to ongoing research and development to enhance product features and user satisfaction in the health and wellness category[86]. Product Development and Innovation - The company launched two new product categories, the meridian gun and the smart moxibustion box "Ginger Xiaozhu A1" during the reporting period[22]. - The company focuses on innovative R&D of portable health products, particularly smart massage devices that integrate advanced technologies[45]. - The company has developed core technologies in precision drive and smart control, health sensing, and human-computer interaction, which are crucial for its product offerings[77][79]. - The company is actively pursuing market expansion through the introduction of multifunctional care devices that can serve dual purposes, such as a neck pillow and a neck massager[82]. - The company aims to enhance product development cycles through the use of specialized embedded systems, significantly shortening the time to market for new applications[81]. - The company is focusing on the development of AI-driven health analysis reports, providing users with personalized health management solutions[102]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 15% increase in market penetration by the end of the fiscal year[162]. Market and Sales Strategy - Online sales grew by 49%, while offline sales increased by 80%, and ODM sales surged by 166%[23]. - The company optimized its marketing strategy and improved brand awareness through targeted marketing and global brand endorsements[23]. - The company has established partnerships with major e-commerce platforms such as JD.com, Tmall, and Amazon to leverage their traffic advantages for online B2C sales[69]. - The company has implemented a multi-channel marketing strategy to enhance brand recognition and consumer engagement[116]. - The company is actively expanding its online sales through partnerships with major e-commerce platforms like Tmall and JD[111]. - The company plans to continue opening new direct stores nationwide to expand its marketing network[125]. Corporate Governance and Compliance - The board of directors has confirmed that there are no significant risks affecting the company's operations during the reporting period[4]. - The report indicates that there are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company does not have any special arrangements for corporate governance that are applicable[8]. - The company has committed to complying with all relevant laws and regulations regarding share transfers[148]. - The company has not disclosed any significant changes in its employee incentive plans or stock ownership plans[143]. - The company has received recognition as a "Provincial Industrial Design Center" by the Guangdong Provincial Department of Industry and Information Technology[95]. Shareholder Information - The actual controller holds 70.57% of the company's shares, which poses a risk of improper control over company decisions[127]. - The profit distribution plan has been approved by the board and requires submission to the shareholders' meeting for final approval[142]. - The company plans to distribute a cash dividend of RMB 4.86 per 10 shares, totaling RMB 29,957,040.00, which represents 16.10% of the distributable profits for the first half of 2021[141]. - The company reported a stock transfer limit of 25% of total shares held by senior management annually during their tenure and for six months post-termination[155]. - The company will announce any intended share reductions three trading days in advance[149]. Financial Position - Total assets amounted to 646.08 million, up 35.67% from the beginning of the year[128]. - Total liabilities increased by 52.95% to 370.65 million, resulting in a debt-to-asset ratio of 57.37%[128]. - The company's total equity attributable to shareholders was RMB 275,933,337.38, up from RMB 234,476,930.83, representing a growth of approximately 17.7%[185]. - Cash and cash equivalents as of June 30, 2021, were RMB 185,204,933.88, compared to RMB 139,290,230.04 at the end of 2020, marking an increase of about 33.0%[183]. - The company's total liabilities to equity ratio was approximately 134.4% as of June 30, 2021, compared to 103.6% at the end of 2020, indicating increased leverage[185].